<DOC>
	<DOCNO>NCT02137629</DOCNO>
	<brief_summary>The main purpose VIDAZA® DUE ( Drug Use Examination ) collect evaluate safety information Korean MDS patient treat VIDAZA® ( SC IV ) accord approve package insert , approval marketing authorization new drug Korea . In addition , efficacy information VIDAZA® clinical practice collect evaluate . This DUE prospective , multi-centre , observational , non-interventional , post-marketing surveillance . At least 600 patient ' data eligible safety assessment collect . VIDAZA® DUE investigate frequency change Adverse Events ( AEs ) /Adverse Drug Reactions ( ADRs ) , Serious Adverse Events ( SAEs ) /Serious Adverse Drug Reactions ( SADRs ) , unexpected AE/ADR unexpected SAE/SADR , scrutinize factor influence safety &amp; efficacy drug . It necessary examine patient ' demographic baseline characteristic , medical history , status VIDAZA treatment , concomitant medication evaluation safety final efficacy ( best response ) assessment .</brief_summary>
	<brief_title>Post Marketing Surveillance Collect Evaluate Safety Efficacy Information Korean MDS Patients Treated With VIDAZA® , After Approval Marketing Authorization New Drug Korea</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Korean male female Myelodysplastic Syndrome patient treat VIDAZA® ( subcutaneous intravenous ) accord approve package insert There 's exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Vidaza</keyword>
	<keyword>Observational study</keyword>
	<keyword>Korea</keyword>
</DOC>